Hormone replacement therapy reduces rates of invasive colorectal cancer
Hormone replacement therapy reduces rates of invasive colorectal cancer
In the Women's Health Initiative, combined estrogen-progestin replacement therapy was associated with a significant reduction in the cumulative hazard of invasive colorectal cancer (hazard ratio 0.56, unadjusted 95 percent CI 0.38 to 0.81).
Data from: Estrogen and progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991.